Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.69 -0.90%

-$0.01 today

Market cap
$116.77M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 11.56M

Average 2.73M

INO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Inovio Pharmaceuticals, Inc.NASDAQ: INO

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $698.74K fell 50.1% year over year, behind the -44.1% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -45.0% a year.

Context

  • Stock-based compensation amounted to 5747.8% of revenue in FY2025, up 2719.1 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -50.1% toward the trailing-twelve-month pace of -44.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$698.74K-8.6% QoQ
Last fiscal yearDec 2025
$3.76M-43.1% YoY
LTMMar 2026
$3.06M-44.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.1%——
1 year-43.1%——
3-year CAGR-45.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
3.76M USD
Year-over-year change
-43.1%
4-year CAGR
-38.5%

Stock-Based Compensation vs competitors

How INO compares with its peers on the latest reported figures

  • INO's LTM Mar 2026 stock-based compensation of $3.06M is the smallest of the 10 companies compared; the peer median is $9.79M.
  • Its year-over-year change of -44.1% is the 8th highest of 10, against a peer median of -43.3%.
  • Over three fiscal years its annual growth of -45.0% compares with a peer median of -16.7%.
INO Competitors Peer median
Stock-Based Compensation for INO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$21.47M -43.3%-31.8%340.0%
ALECAlector, Inc.LTM Mar 2026$21.22M -43.4%-16.7%115.2%
SEERSeer, Inc.LTM Mar 2026$12.88M -49.1%-22.9%85.6%
AGENAgenus Inc.LTM Mar 2026$10.29M -14.6%-1.8%8.3%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$9.79M -43.4%-24.8%853.3%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$9.77M +1.5%+47.6%—
ACTUActuate Therapeutics IncLTM Mar 2026$6.28M +111.2%+109.9%—
IRDOpus Genetics, Inc.LTM Mar 2026$3.95M +20.1%+23.4%33.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$3.88M -47.0%-22.0%7.1%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$3.06M -44.1%-45.0%—
Peer median (excluding INO) $9.79M-43.3%-16.7%85.6%

Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
Deferred Income Tax04.03M(32.05K)00
Stock-Based Compensation26.34M22.56M11.07M6.6M3.76M
Change in Working Capital50.35M19.83M(10.26M)(2.66M)(9.22M)
Accounts Receivables11.03M(3.71M)9.33M1.21M0
Inventory00000
Accounts Payables26.14M32.61M(45.99M)(3.37M)(6.42M)
Other Working Capital13.18M(9.07M)26.4M(504.04K)(2.8M)
Other Non-Cash Items6.53M11.69M6.47M(3.88M)(1.21M)
Operating Cash Flow(215.71M)(216.22M)(124.37M)(104.08M)(88.63M)
Capital Expenditures(1.23M)(969.15K)(320.9K)(487.83K)(285.7K)
Acquisitions (Net)0(2M)6.22M00
Purchases of Investments(348.95M)(248.53M)(203.48M)(54.14M)(4.95M)
Sales of Investments174.84M361.08M284.93M158.64M19.27M
Other Investing Activities00059.32K0
Investing Cash Flow(175.34M)109.59M87.36M104.07M14.04M
Debt Repayment000(16.42M)0
Common Stock Issued209.44M82.96M5.46M68.31M53.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.06M(1.11M)(466.65K)(420.8K)(110.78K)
Financing Cash Flow211.5M81.84M5M51.48M53.05M
Effect of Forex Changes(30.13K)(25.56K)(3.92K)32.4K0
Net Change in Cash(179.58M)(24.81M)(32.02M)51.5M(21.54M)
Free Cash Flow(216.94M)(217.18M)(124.69M)(104.56M)(88.92M)

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Intrinsic Alpha fair value

Locked

Current Price

$1.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.